Claremont BioSolutions Expands Distribution Network with Three New Partnerships

Share Article

Claremont BioSolutions, LLC announced today that it has signed nonexclusive distribution agreements with Gentaur Molecular Products, Ohhana Biotech, and Omics Biotech. The partnerships expand ClaremontBio’s distribution into Europe, Taiwan, and South Korea, respectively.

We are pleased to partner with these leaders in the life science research products market” said Gary Blackburn

Claremont BioSolutions, LLC announced today that it has signed nonexclusive distribution agreements with Gentaur Molecular Products, Ohhana Biotech, and Omics Biotech. The partnerships expand ClaremontBio’s distribution into Europe, Taiwan, and South Korea, respectively. The distributors will market ClaremontBio’s unique products for sample preparation, DNA isolation, and protein purification.

Gentaur, Ohhana, and Omics are leading distributor of life science products and research tools in their respective markets. The companies will offer ClaremontBio’s products to customers in academic, government, and biotech laboratories. ClaremontBio develops, manufactures, and markets next-generation cell lysis, DNA & RNA extraction, and His-tagged protein purification kits and columns.

“We are pleased to partner with these leaders in the life science research products market” said Gary Blackburn, ClaremontBio’s Chief Executive Officer. “Our rapid sample prep solutions have been well received by our customers and we are committed to expanding our product offering to customers worldwide.”

About Claremont BioSolutions.
Claremont BioSolutions (http://www.ClaremontBio.com) is an emerging growth technology company specializing in disposable devices that provide solutions to what is recognized as the “bottleneck” of DNA diagnostics – sample preparation. The company has developed proprietary devices which employ micro-motors to perform very efficient mechanical cell lysis and DNA purification. These devices prepare samples for DNA analysis in less than five minutes and without any extraneous instruments. The technology is readily incorporated into sample-to-answer and “Lab on a Chip” cartridges which will aid the progression of nucleic acid testing into the point of care (POC) market.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Maveety
Visit website